Innovative Pharmaceutical ETF (159992) rebounded, Jiuzhou Pharmaceutical, Yaoming Kangde, and Tiger Pharmaceutical Leading

On September 15, the medical sector rebounded as a whole.Jiuzhou Pharmaceuticals, Yaoming Kangde, and Tiger Pharmaceuticals have risen. Kailai Ying, Kang Longcheng, and Yaoshi Technology have risen, driving innovative medicine ETF (159992) to rise, and the current turnover exceeded 110 million yuan.The market is optimistic about the overall performance of the innovative drug sector, and the net inflow of innovative drug ETF (159992) has a net inflow of 536 million yuan in nearly 20 trading days.

Minsheng Securities stated that when the multi -section of medicine is bottoming, the current rising starting point is the long period of long cycle.At present, the drug collection has reached the post -cycle, and the collection of equipment consumables has also passed the mid -section. Innovative guidance will gradually reflect. Many innovative companies' commercial products have begun to volume. From this year's Q2 situation, the growth of innovative drugs and CXO sectors is still very beautiful.Optimistic about the rise of the bottom of the innovation sector.

- END -